Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
10
×
clinical trials
life sciences
national blog main
new york
10
×
new york blog main
new york top stories
national top stories
fda
san francisco blog main
san francisco top stories
amgen
biotech
inclisiran
regeneron pharmaceuticals
san diego blog main
san diego top stories
sanofi
alnylam pharmaceuticals
cancer
cholesterol
deals
drugs
ipo
novartis
pcsk9
pcsk9 inhibitors
praluent
repatha
the medicines co.
abbvie
achromatopsia
acorda therapeutics
agios pharmaceuticals
akcea therapeutics
alirocumab
allergan
ampyra
antibiotics
What
drug
medicines
fda
new
approved
cholesterol
disease
medco
company
deal
helped
ipo
lowering
meant
medicine
morning
open
past
patients
sets
twice
week
year
aces
acorda
acquire
age
ago
agreed
aim
akcea
alnylam
amyloidosis
announced
attr
available
battle
big
bigger
biggest
Language
unset
Current search:
" new york "
×
" boston top stories "
×
@xconomy.com
4 years ago
Schrödinger Sets Course for IPO to Support Growing Internal Pipeline
@xconomy.com
4 years ago
Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B
@xconomy.com
4 years ago
MedCo Preps for FDA Filing as Cholesterol Drug Clears Last Two Tests
@xconomy.com
4 years ago
As Cholesterol Drug Aces Big Test, MedCo CEO Open to Flexible Pricing
@xconomy.com
5 years ago
FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea
@xconomy.com
5 years ago
With New Data, Intercept On Track for First-Ever Approved NASH Drug
@xconomy.com
5 years ago
With $100M MeiraGTx Deal, J&J Signals Bigger Move Into Gene Therapy
@xconomy.com
5 years ago
Acorda Gets FDA Nod For New Parkinson’s Drug, But Rival Looms
@xconomy.com
5 years ago
Six Life Science Firms Close Q3 with an IPO, More Are on the Way
@xconomy.com
5 years ago
With OneOncology, Flatiron and Cancer Docs Aim to Boost Community Care